Imaging  ||| S:0 E:8 ||| JJ
blood-brain  ||| S:8 E:20 ||| JJ
barrier  ||| S:20 E:28 ||| NN
dysfunction  ||| S:28 E:40 ||| NN
in  ||| S:40 E:43 ||| IN
animal  ||| S:43 E:50 ||| JJ
disease  ||| S:50 E:58 ||| NN
models  ||| S:58 E:65 ||| NNS
The  ||| S:65 E:69 ||| DT
blood-brain  ||| S:69 E:81 ||| JJ
barrier  ||| S:81 E:89 ||| NN
( ||| S:89 E:90 ||| -LRB-
BBB ||| S:90 E:93 ||| NNP
)  ||| S:93 E:95 ||| -RRB-
is  ||| S:95 E:98 ||| VBZ
a  ||| S:98 E:100 ||| DT
highly  ||| S:100 E:107 ||| RB
complex  ||| S:107 E:115 ||| JJ
structure ||| S:115 E:124 ||| NN
,  ||| S:124 E:126 ||| ,
which  ||| S:126 E:132 ||| WDT
separates  ||| S:132 E:142 ||| VBZ
the  ||| S:142 E:146 ||| DT
extracellular  ||| S:146 E:160 ||| JJ
fluid  ||| S:160 E:166 ||| NN
of  ||| S:166 E:169 ||| IN
the  ||| S:169 E:173 ||| DT
central  ||| S:173 E:181 ||| JJ
nervous  ||| S:181 E:189 ||| JJ
system  ||| S:189 E:196 ||| NN
( ||| S:196 E:197 ||| -LRB-
CNS ||| S:197 E:200 ||| NNP
)  ||| S:200 E:202 ||| -RRB-
from  ||| S:202 E:207 ||| IN
the  ||| S:207 E:211 ||| DT
blood  ||| S:211 E:217 ||| NN
of  ||| S:217 E:220 ||| IN
CNS  ||| S:220 E:224 ||| NNP
vessels ||| S:224 E:231 ||| NNS
.  ||| S:231 E:233 ||| .
A  ||| S:233 E:235 ||| DT
wide  ||| S:235 E:240 ||| JJ
range  ||| S:240 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
neurologic  ||| S:249 E:260 ||| JJ
conditions ||| S:260 E:270 ||| NNS
,  ||| S:270 E:272 ||| ,
including  ||| S:272 E:282 ||| VBG
stroke ||| S:282 E:288 ||| NN
,  ||| S:288 E:290 ||| ,
epilepsy ||| S:290 E:298 ||| NN
,  ||| S:298 E:300 ||| ,
Alzheimer ||| S:300 E:309 ||| NNP
's  ||| S:309 E:312 ||| POS
disease ||| S:312 E:319 ||| NN
,  ||| S:319 E:321 ||| ,
and  ||| S:321 E:325 ||| CC
brain  ||| S:325 E:331 ||| NN
tumors ||| S:331 E:337 ||| NNS
,  ||| S:337 E:339 ||| ,
are  ||| S:339 E:343 ||| VBP
associated  ||| S:343 E:354 ||| VBN
with  ||| S:354 E:359 ||| IN
perturbations  ||| S:359 E:373 ||| NN
of  ||| S:373 E:376 ||| IN
the  ||| S:376 E:380 ||| DT
BBB  ||| S:380 E:384 ||| NNP
that  ||| S:384 E:389 ||| WDT
contribute  ||| S:389 E:400 ||| VBP
to  ||| S:400 E:403 ||| TO
their  ||| S:403 E:409 ||| PRP$
pathology ||| S:409 E:418 ||| NN
.  ||| S:418 E:420 ||| .
The  ||| S:420 E:424 ||| DT
common  ||| S:424 E:431 ||| JJ
consequence  ||| S:431 E:443 ||| NN
of  ||| S:443 E:446 ||| IN
a  ||| S:446 E:448 ||| DT
BBB  ||| S:448 E:452 ||| NNP
dysfunction  ||| S:452 E:464 ||| NN
is  ||| S:464 E:467 ||| VBZ
increased  ||| S:467 E:477 ||| VBN
permeability ||| S:477 E:489 ||| NN
,  ||| S:489 E:491 ||| ,
leading  ||| S:491 E:499 ||| VBG
to  ||| S:499 E:502 ||| TO
extravasation  ||| S:502 E:516 ||| VB
of  ||| S:516 E:519 ||| IN
plasma  ||| S:519 E:526 ||| JJ
constituents  ||| S:526 E:539 ||| NNS
and  ||| S:539 E:543 ||| CC
vasogenic  ||| S:543 E:553 ||| JJ
brain  ||| S:553 E:559 ||| NN
edema ||| S:559 E:564 ||| NN
.  ||| S:564 E:566 ||| .
The  ||| S:566 E:570 ||| DT
BBB  ||| S:570 E:574 ||| NNP
impairment  ||| S:574 E:585 ||| NN
can  ||| S:585 E:589 ||| MD
persist  ||| S:589 E:597 ||| VB
for  ||| S:597 E:601 ||| IN
long  ||| S:601 E:606 ||| JJ
periods ||| S:606 E:613 ||| NNS
,  ||| S:613 E:615 ||| ,
being  ||| S:615 E:621 ||| VBG
involved  ||| S:621 E:630 ||| VBN
in  ||| S:630 E:633 ||| IN
secondary  ||| S:633 E:643 ||| JJ
inflammation  ||| S:643 E:656 ||| NN
and  ||| S:656 E:660 ||| CC
neuronal  ||| S:660 E:669 ||| JJ
dysfunction ||| S:669 E:680 ||| NN
,  ||| S:680 E:682 ||| ,
thus  ||| S:682 E:687 ||| RB
contributing  ||| S:687 E:700 ||| VBG
to  ||| S:700 E:703 ||| TO
disease  ||| S:703 E:711 ||| NN
pathogenesis ||| S:711 E:723 ||| NN
.  ||| S:723 E:725 ||| .
Therefore ||| S:725 E:734 ||| RB
,  ||| S:734 E:736 ||| ,
reliable  ||| S:736 E:745 ||| JJ
imaging  ||| S:745 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
the  ||| S:756 E:760 ||| DT
BBB  ||| S:760 E:764 ||| NNP
impairment  ||| S:764 E:775 ||| NN
is  ||| S:775 E:778 ||| VBZ
of  ||| S:778 E:781 ||| IN
major  ||| S:781 E:787 ||| JJ
importance  ||| S:787 E:798 ||| NN
in  ||| S:798 E:801 ||| IN
both  ||| S:801 E:806 ||| DT
clinical  ||| S:806 E:815 ||| JJ
management  ||| S:815 E:826 ||| NN
of  ||| S:826 E:829 ||| IN
brain  ||| S:829 E:835 ||| NN
diseases  ||| S:835 E:844 ||| NNS
and  ||| S:844 E:848 ||| CC
in  ||| S:848 E:851 ||| IN
experimental  ||| S:851 E:864 ||| JJ
research ||| S:864 E:872 ||| NN
.  ||| S:872 E:874 ||| .
From  ||| S:874 E:879 ||| IN
landmark  ||| S:879 E:888 ||| NN
studies  ||| S:888 E:896 ||| NNS
by  ||| S:896 E:899 ||| IN
Ehrlich  ||| S:899 E:907 ||| NNP
and  ||| S:907 E:911 ||| CC
Goldman ||| S:911 E:918 ||| NNP
,  ||| S:918 E:920 ||| ,
the  ||| S:920 E:924 ||| DT
use  ||| S:924 E:928 ||| NN
of  ||| S:928 E:931 ||| IN
dyes  ||| S:931 E:936 ||| NNS
( ||| S:936 E:937 ||| -LRB-
probes ||| S:937 E:943 ||| LS
)  ||| S:943 E:945 ||| -RRB-
has  ||| S:945 E:949 ||| VBZ
played  ||| S:949 E:956 ||| VBN
a  ||| S:956 E:958 ||| DT
critical  ||| S:958 E:967 ||| JJ
role  ||| S:967 E:972 ||| NN
in  ||| S:972 E:975 ||| IN
understanding  ||| S:975 E:989 ||| VBG
BBB  ||| S:989 E:993 ||| NNP
functions ||| S:993 E:1002 ||| NNS
.  ||| S:1002 E:1004 ||| .
In  ||| S:1004 E:1007 ||| IN
recent  ||| S:1007 E:1014 ||| JJ
years  ||| S:1014 E:1020 ||| NNS
methodologic  ||| S:1020 E:1033 ||| JJ
advances  ||| S:1033 E:1042 ||| NNS
in  ||| S:1042 E:1045 ||| IN
morphologic  ||| S:1045 E:1057 ||| NN
and  ||| S:1057 E:1061 ||| CC
functional  ||| S:1061 E:1072 ||| JJ
brain  ||| S:1072 E:1078 ||| NN
imaging  ||| S:1078 E:1086 ||| NNS
have  ||| S:1086 E:1091 ||| VBP
provided  ||| S:1091 E:1100 ||| VBN
insight  ||| S:1100 E:1108 ||| VBN
into  ||| S:1108 E:1113 ||| IN
cellular  ||| S:1113 E:1122 ||| JJ
and  ||| S:1122 E:1126 ||| CC
molecular  ||| S:1126 E:1136 ||| JJ
interactions  ||| S:1136 E:1149 ||| NNS
underlying  ||| S:1149 E:1160 ||| VBG
BBB  ||| S:1160 E:1164 ||| NNP
dysfunction  ||| S:1164 E:1176 ||| NN
in  ||| S:1176 E:1179 ||| IN
animal  ||| S:1179 E:1186 ||| JJ
disease  ||| S:1186 E:1194 ||| NN
models ||| S:1194 E:1200 ||| NNS
.  ||| S:1200 E:1202 ||| .
These  ||| S:1202 E:1208 ||| DT
imaging  ||| S:1208 E:1216 ||| JJ
techniques ||| S:1216 E:1226 ||| NNS
,  ||| S:1226 E:1228 ||| ,
which  ||| S:1228 E:1234 ||| WDT
range  ||| S:1234 E:1240 ||| VBP
from  ||| S:1240 E:1245 ||| IN
in  ||| S:1245 E:1248 ||| IN
situ  ||| S:1248 E:1253 ||| JJ
staining  ||| S:1253 E:1262 ||| NN
to  ||| S:1262 E:1265 ||| TO
noninvasive  ||| S:1265 E:1277 ||| VB
in  ||| S:1277 E:1280 ||| IN
vivo  ||| S:1280 E:1285 ||| JJ
imaging ||| S:1285 E:1292 ||| NN
,  ||| S:1292 E:1294 ||| ,
have  ||| S:1294 E:1299 ||| VBP
different  ||| S:1299 E:1309 ||| JJ
spatial  ||| S:1309 E:1317 ||| JJ
resolution ||| S:1317 E:1327 ||| NN
,  ||| S:1327 E:1329 ||| ,
sensitivity ||| S:1329 E:1340 ||| NN
,  ||| S:1340 E:1342 ||| ,
and  ||| S:1342 E:1346 ||| CC
capacity  ||| S:1346 E:1355 ||| NN
for  ||| S:1355 E:1359 ||| IN
quantitative  ||| S:1359 E:1372 ||| JJ
and  ||| S:1372 E:1376 ||| CC
kinetic  ||| S:1376 E:1384 ||| JJ
measures  ||| S:1384 E:1393 ||| NNS
of  ||| S:1393 E:1396 ||| IN
the  ||| S:1396 E:1400 ||| DT
BBB  ||| S:1400 E:1404 ||| NNP
impairment ||| S:1404 E:1414 ||| NN
.  ||| S:1414 E:1416 ||| .
Despite  ||| S:1416 E:1424 ||| IN
significant  ||| S:1424 E:1436 ||| JJ
advances ||| S:1436 E:1444 ||| NNS
,  ||| S:1444 E:1446 ||| ,
the  ||| S:1446 E:1450 ||| DT
translation  ||| S:1450 E:1462 ||| NN
of  ||| S:1462 E:1465 ||| IN
these  ||| S:1465 E:1471 ||| DT
techniques  ||| S:1471 E:1482 ||| NNS
into  ||| S:1482 E:1487 ||| IN
clinical  ||| S:1487 E:1496 ||| JJ
applications  ||| S:1496 E:1509 ||| NNS
remains  ||| S:1509 E:1517 ||| VBZ
slow ||| S:1517 E:1521 ||| JJ
.  ||| S:1521 E:1523 ||| .
This  ||| S:1523 E:1528 ||| DT
review  ||| S:1528 E:1535 ||| NN
outlines  ||| S:1535 E:1544 ||| VBZ
key  ||| S:1544 E:1548 ||| JJ
recent  ||| S:1548 E:1555 ||| JJ
advances  ||| S:1555 E:1564 ||| NNS
in  ||| S:1564 E:1567 ||| IN
imaging  ||| S:1567 E:1575 ||| JJ
techniques  ||| S:1575 E:1586 ||| NNS
that  ||| S:1586 E:1591 ||| WDT
have  ||| S:1591 E:1596 ||| VBP
contributed  ||| S:1596 E:1608 ||| VBN
to  ||| S:1608 E:1611 ||| TO
the  ||| S:1611 E:1615 ||| DT
understanding  ||| S:1615 E:1629 ||| NN
of  ||| S:1629 E:1632 ||| IN
BBB  ||| S:1632 E:1636 ||| NNP
dysfunction  ||| S:1636 E:1648 ||| NN
in  ||| S:1648 E:1651 ||| IN
disease  ||| S:1651 E:1659 ||| NN
and  ||| S:1659 E:1663 ||| CC
discusses  ||| S:1663 E:1673 ||| JJ
major  ||| S:1673 E:1679 ||| JJ
obstacles  ||| S:1679 E:1689 ||| NNS
and  ||| S:1689 E:1693 ||| CC
opportunities  ||| S:1693 E:1707 ||| NNS
to  ||| S:1707 E:1710 ||| TO
advance  ||| S:1710 E:1718 ||| VB
these  ||| S:1718 E:1724 ||| DT
techniques  ||| S:1724 E:1735 ||| NNS
into  ||| S:1735 E:1740 ||| IN
the  ||| S:1740 E:1744 ||| DT
clinical  ||| S:1744 E:1753 ||| JJ
realm ||| S:1753 E:1758 ||| NN
.  ||| S:1758 E:1760 ||| .
